<?xml version="1.0" encoding="UTF-8"?>
<p id="para0026">Preliminary studies in a small number of patients have shown beneficial effects of transfusion of plasma from patients who have recovered from COVID-19 on viral load, radiological findings, and survival of patients with severe COVID-19 [
 <xref rid="bib0044" ref-type="bibr">44</xref>,
 <xref rid="bib0045" ref-type="bibr">45</xref>]. However, the beneficial effects have not been observed consistently 
 <xref rid="bib0046" ref-type="bibr">[46]</xref>. Over 50 clinical trials, including two dozen phase 3 studies, are currently underway and two randomized studies have been concluded with inconclusive findings [
 <xref rid="bib0046" ref-type="bibr">46</xref>,
 <xref rid="bib0047" ref-type="bibr">47</xref>]. Based on the safety profile, preclinical data, nonrandomized studies, and considering subgroup data in a randomized clinical trial, the Food and Drug Administration (FDA) recently approved convalescent plasma from COVID-19 patients as a “may be effective” treatment in hospitalized patients with COVID-19.
</p>
